PIK3CA and breast cancer: Among these, two trials stand out (NCT04208178 and ALPHABET, and NCT05063786) for studying the use of alpelisib (PI3K inhibitor) in HER2 advanced BC with PIK3CA mutations and resistance to trastuzumab and pertuzumab or to T-DM1, respectively.